Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms

被引:10
作者
Kim, Eun Ran [1 ]
Yang, Mun Hee [2 ]
Lim, Yeun Jung [2 ]
Lee, Jin Hee [1 ]
Chang, Dong Kyung [1 ]
Kim, Young-Ho [1 ]
Son, Hee Jung [1 ]
Kim, Jae J. [1 ]
Rhee, Jong Chul [1 ]
Kim, Jin Yong [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Ctr Hlth Promot, Seoul 135710, South Korea
关键词
Plasminogen activator inhibitor 1; Colorectal neoplasms; PAI-1; EXPRESSION; UROKINASE; CANCER; SYSTEM; ADENOMA; MARKERS; COLON; RISK;
D O I
10.5009/gnl.2013.7.5.519
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Plasminogen activator inhibitor-1 (PAI-1) is important for tumor growth, Invasion, and metastasis. In this study, we investigated the relationship between plasma levels of PAI-1 and colorectal adenomas. Methods: We reviewed the medical records of 3,136 subjects who underwent colonoscopy as a screening exam. The subjects were classified into a case group with adenomas (n=990) and a control group (n=2,146). Plasma PAI-1 levels were categorized into three groups based on tertile. Results: The plasma levels of PAI-1 were significantly higher in adenoma cases than in controls (p=0.023). The prevalence of colorectal adenomas increased significantly with increasing levels of PAI-1 (p=0.038). In the adenoma group, advanced pathologic features, size, and number of adenomas did not differ among the three groups based on tertiles for plasma PAI-1 levels. Using multivariate analysis, we found that plasma level of PAI-1 was not associated with the risk of colorectal adenomas (p=0.675). Adjusted odds ratios for colorectal adenomas according to increasing plasma levels of PAI-1 were 0.980 (95% confidence interval [CI], 0.768 to 1.251) for the second-highest plasma level and 1.091 (95% CI, 0.898 to 1.326) for the highest level, compared with the lowest levels. Conclusions: These results suggest that elevated plasma PAI-1 levels are not associated with the risk of colorectal neoplasms.
引用
收藏
页码:519 / 523
页数:5
相关论文
共 21 条
[1]   PAI-1 - A potential therapeutic target in cancer [J].
Andreasen, Peter A. .
CURRENT DRUG TARGETS, 2007, 8 (09) :1030-1041
[2]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[3]   The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology [J].
Baker, EA ;
Leaper, DJ .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (07) :981-988
[4]   The plasminogen activator inhibitor "paradox" in cancer [J].
Binder, Bernd R. ;
Mihaly, Judit .
IMMUNOLOGY LETTERS, 2008, 118 (02) :116-124
[5]  
DEBRUIN PAF, 1987, CANCER RES, V47, P4654
[6]   The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer [J].
Duffy, MJ ;
Duggan, C .
CLINICAL BIOCHEMISTRY, 2004, 37 (07) :541-548
[7]   Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer [J].
Foersti, A. ;
Lei, H. ;
Tavelin, B. ;
Enquist, K. ;
Palmqvist, R. ;
Altieri, A. ;
Hallmans, G. ;
Hemminki, K. ;
Lenner, P. .
ANNALS OF ONCOLOGY, 2007, 18 (12) :1990-1994
[8]   Differential Prognostic Impact of uPA and PAI-1 in Colon and Rectal Cancer [J].
Langenskiold, Marcus ;
Holmdahl, Lena ;
Angenete, Eva ;
Falk, Peter ;
Nordgren, Svante ;
Ivarsson, Marie-Louise .
TUMOR BIOLOGY, 2009, 30 (04) :210-220
[9]   Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population [J].
Liu, Chiu-Shong ;
Hsu, Hua-Shui ;
Li, Chia-Ing ;
Jan, Chia-Ing ;
Li, Tsai-Chung ;
Lin, Wen-Yuan ;
Lin, Tsann ;
Chen, Ya-Chien ;
Lee, Cheng-Chun ;
Lin, Cheng-Chieh .
BMC GASTROENTEROLOGY, 2010, 10
[10]   Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis [J].
Loktionov, A ;
Watson, MA ;
Stebbings, WSL ;
Speakman, CTM ;
Bingham, SA .
CANCER LETTERS, 2003, 189 (02) :189-196